Greater understanding of the pathogenesis of calcific aortic valve stenosis (CAVS) – leading to development of new pharmaceuticals and earlier intervention to stave off progression – is an meaningful goal for better managing this common debilitating condition. So contend two leading CAVS experts in a recently published State-of-the-Art Review in the Journal of the American College of Cardiology (JACC) (2025;86[9]:659-672).

“We are starting to appreciate that CAVS is not simply a passive degenerative process associated with aging but that it involves active mechanisms that may be amenable to intervention,” says Milind Desai, MD, MBA, Vice-Chair, Heart, Vascular and thoracic Institute, Cleveland Clinic, who co-authored the review with Eugene Braunwald, MD, of Brigham and Women’s Hospital in Boston. “We believe we can improve on the current commonly employed strategy of watchful waiting until patients become eligible for aortic valve replacement.”

The review details the epidemiology of CAVS, current understanding of its underlying mechanisms, its typical course and the latest thinking on how to improve assessment of disease severity and management. Potential new pharmaceutical agents and imaging strategies are also discussed.

## Identifying potential new treatment targets

Multiple overlapping processes appear to contribute to the initiation and propagation of aortic valve leaflet calcification. They include oxidative stress, lipopro“`html

Sodium fluoride Positron Emission Tomography (¹⁸F-NaF PET) for Early Disease Detection

Positron emission tomography (PET) using sodium fluoride (¹⁸F-NaF) is emerging as a promising technique for detecting early disease activity, particularly in bone. Unlike traditional imaging methods that often visualize structural changes occurring after significant disease progression, ¹⁸F-NaF PET detects changes in bone metabolism, perhaps identifying disease at a much earlier stage. This makes it a valuable tool for research and, increasingly, clinical applications.

How ¹⁸F-NaF PET Works

¹⁸F-NaF is a radiotracer, meaning it’s a radioactive substance used to image biological processes. Fluoride ions, when introduced into the body, are attracted to areas of active bone turnover. This turnover occurs when bone is being formed or broken down, a process that is often heightened in the presence of disease.

here’s a breakdown of the process:

• Radiotracer Injection: A small amount of ¹⁸F-NaF is injected into the patient’s bloodstream.
• Uptake: The tracer travels through the body and accumulates in areas of increased bone metabolism.
• PET Scan: The patient lies in a PET scanner, which detects the positrons emitted by the radioactive fluorine.
• Image Reconstruction: A computer processes the detected signals to create detailed images showing the distribution of ¹⁸F-NaF in the bones.

Areas with higher ¹⁸F-NaF uptake indicate increased bone metabolic activity, which can be a sign of early disease.

Applications of ¹⁸F-naf PET

While research is ongoing, ¹⁸F-NaF PET is showing promise in several areas:

Cancer Detection and Staging

¹⁸F-NaF PET can detect bone metastases (cancer that has spread to the bone) earlier than traditional bone scans. This is particularly useful in cancers known to frequently metastasize to bone, such as breast cancer, prostate cancer, and lung cancer. It can also help assess the response to cancer treatment.

inflammatory and autoimmune Diseases

Conditions like rheumatoid arthritis and spondyloarthritis involve inflammation that affects the bones. ¹⁸F-NaF PET can visualize this inflammation, potentially aiding in diagnosis and monitoring disease progression.

Cardiovascular Disease

Emerging research suggests a link between bone metabolism and cardiovascular disease. ¹⁸F-NaF PET might potentially be able to detect early signs of calcium buildup in arteries, a precursor to atherosclerosis (hardening of the arteries).

Advantages of ¹⁸F-NaF PET

• Early Detection: Detects disease activity before structural changes are visible on conventional imaging.
• High Sensitivity: More sensitive than traditional bone scans in detecting subtle changes in bone metabolism.
• Whole-Body Imaging: Can scan the entire skeleton in a single session.

Limitations and Considerations

While promising, ¹⁸F-NaF PET has some limitations:

• Radiation Exposure: As with all PET scans, there is exposure to a small amount of radiation.
• Availability: ¹⁸F-NaF PET is not widely available,as it requires specialized equipment and expertise.
• Cost: PET scans are generally more expensive than other imaging modalities.
• Specificity: Increased uptake can be seen in benign conditions as well as disease, requiring careful interpretation.

future Directions

Ongoing research is focused on refining ¹⁸F-NaF